JUL 10, 2018 09:00 PM PDT

Risk Allele Variant SNP at 14q11.2 Linked to ALL

Acute Lymphoblastic Leukemia, or ALL, is a B-cell disorder that affects pediatric patients and is the most common childhood cancer diagnosed.  Patients with this diagnosis produce too many immature B-cells; a process driven by genetic mutations or predisposing factors.  It is well established that around 60% of ALL diagnoses are found to have the presence of a translocation between chromosomes 12 and 21, which produces the commonly characterized chimeric ETV6-RUNX1 protein. Another genetic change occurs in a smaller percentage of patients that involves a translocation of chromosomes 5 and 14, which affect genes in the immunoglobulin heavy chain and interleukin-3. 

A new study just published July 6, 2018 in the journal Leukemia examined ALL and genetic risk factors, specifically locations of genetic variants and their potential association with the disease.  The authors of the study utilized genome-wide association studies (GWAS) to identify 11 specific loci linked to ALL.  The loci are all located in proximity to B-cell development genes.  The authors of the study identified an at-risk locus at 14q11.2, which encodes a gene called CCAAT enhancer-binding protein epsilon (CEBPE).  The CEBPE protein produced regulates a distinct pattern of nucleotides (CCAAT) that act as a promoter region for other genes. When the protein is upregulated, as in ALL, the promoter region is turned on and continues to promote early B-cell proliferation which becomes uncontrolled.  There is a specific single nucleotide polymorphism identified that enhances that CEBPE promoter region.  The variant, rs2239630, has an adenine inserted where a guanine should be.  This 14q11.2 SNP risk allele affects granulocyte differentiation and myelopoetic defects.  Ultimately, CEPBE differential expression may provide a basis for the 14q11.2 risk connected with ALL. 

Scientific advances is sequencing genes could provide an opportunity to better predict and monitor potential patients who carry the variant allele associated in this case.  Early diagnosis and treatment is key for children with ALL.

Sources: Leukemia, National Cancer Institute, NCBI dbSNP, Leukemia & Lymphoma Society, Hematology/Oncology Clinics of North America,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 26, 2018
Clinical & Molecular DX
MAY 26, 2018
Calculate Your Risk For Lung Cancer
A new tool may help reduce the use of CT scans in lung cancer detection, which can cause harm....
MAY 29, 2018
Cancer
MAY 29, 2018
Obesity Directly Linked as a Risk Factor in 13 Cancers
Obesity, and the factors that lead up the state of being obese, contribute to physiological function; the literature supports the claims that this increases risk for development of cancer....
JUN 16, 2018
Cancer
JUN 16, 2018
Lung Cancer Rates Increasing in White and Hispanic Young Women
Lung cancer has long been tied to smoking and had a higher incidence in men than women. A new study shows rates of lung cancer are increasing in some groups of young women....
JUN 26, 2018
Cancer
JUN 26, 2018
Genomic Markers Identified for Infant Soft Tissue Tumors
A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between infant soft tissue tumors and the mutations involving EGFR and BRAF gene...
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
AUG 14, 2018
Cancer
AUG 14, 2018
Using Arsenic to Enhance Cancer Therapies Beyond Leukemia
An already existing combination of arsenic and all-trans retinoic acid is found to inhibit a key signaling pathway that exerts broad effect on oncogenic processes for some solid tumors....
Loading Comments...